Edesa Biotech announces findings from in vitro study of paridiprubart

Edesa Biotech announced findings from an in vitro study of its monoclonal antibody candidate, paridiprubart, against a panel of respiratory pathogens. The study was completed by the University of Toronto in parallel to the company’s ongoing clinical study of EB05 in hospitalized Covid-19 patients with Acute Respiratory Distress Syndrome, a severe form of respiratory failure characterized by widespread inflammatory injury to the lungs. Approximately 10% of all ICU admissions are ARDS related. The research results available today in preprint demonstrated that multiple pathogens, including Influenza A, coronavirus and a common bacterium, can initiate an overactive immune response through Toll-like Receptor 4, a key component of the innate immune system. More importantly, the study determined that inflammation signaling from each of these pathogens was inhibited by Edesa’s TLR4 antagonist, paridiprubart. Paridiprubart represents a new class of emerging therapies called Host-Directed Therapeutics that are designed to modulate the body’s own immune response when confronted with infectious diseases or even chemical agents. Importantly, these therapies are designed to work across multiple infectious diseases and threats, and could be stockpiled preemptively ahead of outbreaks.